Effect of Hyoscine- Bromide on Duration of the First Stage of Labor

Launched by AIN SHAMS UNIVERSITY · Sep 21, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the effect of a medication called hyoscine butylbromide (HBB) on the length of the first stage of labor for first-time mothers. The goal is to see if HBB can help reduce the time it takes for the cervix to open during labor, which can sometimes be slowed down by muscle spasms. Women who are eligible for this study must be first-time mothers with a single baby in the correct position, between 37 and 42 weeks pregnant, and currently in active labor with some cervical dilation.

Participants in this trial can expect to receive either the medication or a placebo (a non-active treatment) to see how it affects their labor. The trial is currently recruiting women who meet the eligibility criteria, and it’s important to note that those with certain medical conditions or previous surgeries may not qualify. Overall, this study aims to provide valuable information that could help improve labor experiences for future mothers.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Primigravid women.
• • 2. Singleton pregnancy.
• • 3. Presenting by the vertex.
• • 4. Gestational age between 37 and 42 weeks
• • 5. In active phase of labor with a cervical dilatation between 4-5 cm, with either intact membranes or spontaneous rupture of membranes for less than 12 h
• Exclusion Criteria:
• • 1. Previous uterine scarring.
• • 2. Malpresentation.
• • 3. Antepartum hemorrhage.
• • 4. Labor induction
• • 5. Contraindication to vaginal delivery.
• • 6. Contraindication to hyoscine.